Answers are grounded in this paper and cite their sources.
Background Atrophic gastritis (AG), characterized by chronic inflammation of the gastric mucosa and glandular atrophy, is an established precursor of gastric cancer (GC) and contributes to iron-deficiency anemia, vitamin B12 deficiency, and pernicious anemia. Although Helicobacter pylori infection is a major environmental determinant, not all infected individuals develop AG or GC, suggesting that host genetic factors influence susceptibility to AG and severe atrophic gastritis (SAG). Previous genome-wide association studies (GWAS) of AG have been limited in size and have not adequately compared anti-H. pylori IgG serostatus strata, leaving potential genetic heterogeneity unresolved. Methods We performed GWAS meta-analyses of AG and SAG, stratified by anti-H. pylori IgG serostatus, involving 214,747 Japanese participants: 75,074 in the discovery phase and 139,673 in the replication phase. Subsequent analyses included genotype-by-serostatus interactions, HLA allele and ABO blood group associations, genome-wide genetic correlations, multi-trait analysis, local genetic correlations, and structural equation modeling. In addition, cross-ancestry meta-analyses were performed using chronic gastritis GWAS data from FinnGen, UK Biobank, and the Million Veteran Program, comprising 1,357,053 participants. Results Across six Japanese GWAS meta-analyses, we identified genome-wide significant associations at 17 genomic regions. Strong associations with seropositive AG/SAG were observed at previously reported GC susceptibility loci, including PSCA and MUC1/MTX1, whereas the MHC class II region showed predominant associations with seronegative AG/SAG. FAP, CCR6, and ATP4A were also found to be associated with seronegative SAG. The identified regions included previously reported GC susceptibility regions MUC1/MTX1, PRKAA1/PTGER4, PSCA, ABO, and MHC. Associations at PSCA and MUC1/MTX1 were replicated at a genome-wide significance level, supporting a shared genetic basis between AG/SAG and GC. Additional AG-associated candidate regions included BMP2, CCDC80, LRRC34, CPEB4, PGC/FRS3, and LMTK2, implicating epithelial regulation, immune responses, transcriptional regulation, and differentiation. A positive genotype-by-serostatus interaction for SAG was observed at MUC1/MTX1. HLA class II alleles, including HLA-DRB1*15:01 and HLA-DQB1*06:02, showed associations with seronegative AG/SAG. The LDSC genetic correlation between AG and GC was 0.529, and the MTAG estimated Omega correlation was 0.694. Local genetic correlation analysis and structural equation modeling further supported shared genetic components. Cross-ancestry integration of seronegative SAG with external chronic gastritis GWAS data identified an additional association at TPTEP1. Conclusions Our findings characterize the genetic heterogeneity of serologically defined AG/SAG according to anti-H. pylori IgG serostatus. They highlight epithelial and mucus barrier-related pathways in seropositive AG/SAG and immune-related pathways in seronegative cases, while also providing evidence of a shared genetic basis between AG and GC. Together, these results clarify the genetic basis of a GC precursor and are consistent with a continuum from chronic inflammation through atrophy to carcinogenesis. These insights may inform prevention strategies and personalized management of the diverse health consequences of AG.
No takes yet. Share an insight, caveat, or question.
Kyosaka et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: